A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) ; volume:23 ; number:1 ; day:25 ; month:7 ; year:2024 ; pages:1-12 ; date:7.2024
BMC cancer ; 23, Heft 1 (25.7.2024), 1-12, 7.2024

Creator: Lara, Primo N.
Villanueva, Luis
Ibanez, Carolina
Erman, Mustafa
Lee, Jae Lyun
Heinrich, Daniel
Lipatov, Oleg Nikolaevich
Gedye, Craig
Gokmen, Erhan
Acevedo, Alejandro
Semenov, Andrey
Park, Se Hoon
Gafanov, Rustem Airatovich
Kose, Fatih
Jones, Mark
Du, Xiaoqi
Munteanu, Mihaela
Perini, Rodolfo
Choueiri, Toni K.
Motzer, Robert J.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-023-10971-7

URN: urn:nbn:de:101:1-2410102124045.138800934042

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:39 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lara, Primo N.
Villanueva, Luis
Ibanez, Carolina
Erman, Mustafa
Lee, Jae Lyun
Heinrich, Daniel
Lipatov, Oleg Nikolaevich
Gedye, Craig
Gokmen, Erhan
Acevedo, Alejandro
Semenov, Andrey
Park, Se Hoon
Gafanov, Rustem Airatovich
Kose, Fatih
Jones, Mark
Du, Xiaoqi
Munteanu, Mihaela
Perini, Rodolfo
Choueiri, Toni K.
Motzer, Robert J.
SpringerLink (Online service)

Other Objects (12)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Hochschulschrift

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Hochschulschrift

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Hochschulschrift

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Related objects

Reset password